BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24375774)

  • 1. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
    Pasoglou V; Larbi A; Collette L; Annet L; Jamar F; Machiels JP; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
    Prostate; 2014 May; 74(5):469-77. PubMed ID: 24375774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
    Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
    Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
    AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
    Lecouvet FE; Geukens D; Stainier A; Jamar F; Jamart J; d'Othée BJ; Therasse P; Vande Berg B; Tombal B
    J Clin Oncol; 2007 Aug; 25(22):3281-7. PubMed ID: 17664475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative.
    Eyrich NW; Tosoian JJ; Drobish J; Montie JE; Qi J; Kim T; Noyes SL; Moriarity AK; Lane BR;
    Urol Oncol; 2020 Jul; 38(7):636.e13-636.e19. PubMed ID: 32067844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma.
    Müller-Horvat C; Radny P; Eigentler TK; Schäfer J; Pfannenberg C; Horger M; Khorchidi S; Nägele T; Garbe C; Claussen CD; Schlemmer HP
    Eur J Cancer; 2006 Feb; 42(3):342-50. PubMed ID: 16364631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
    Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
    Pfannenberg C; Aschoff P; Schanz S; Eschmann SM; Plathow C; Eigentler TK; Garbe C; Brechtel K; Vonthein R; Bares R; Claussen CD; Schlemmer HP
    Eur J Cancer; 2007 Feb; 43(3):557-64. PubMed ID: 17224266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature.
    Giannarini G; Petralia G; Thoeny HC
    Eur Urol; 2012 Feb; 61(2):326-40. PubMed ID: 22000497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
    Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report.
    Belmonte M; Saia G; Zugni F; Alessi S; Colombo A; Summers PE; Luzzago S; Marvaso G; Musi G; De Cobelli O; Jereczek-Fossa BA; Petralia G
    Acta Biomed; 2021 Sep; 92(4):e2021214. PubMed ID: 34487080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI - local staging of prostate cancer and beyond.
    Caglic I; Kovac V; Barrett T
    Radiol Oncol; 2019 May; 53(2):159-170. PubMed ID: 31103999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
    Harisinghani MG; Barentsz J; Hahn PF; Deserno WM; Tabatabaei S; van de Kaa CH; de la Rosette J; Weissleder R
    N Engl J Med; 2003 Jun; 348(25):2491-9. PubMed ID: 12815134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate.
    Kuru TH; Roethke MC; Rieker P; Roth W; Fenchel M; Hohenfellner M; Schlemmer HP; Hadaschik BA
    BJU Int; 2013 Dec; 112(8):1080-7. PubMed ID: 23937255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
    Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
    J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease.
    Stevenson JD; Watson JJ; Cool P; Cribb GL; Jenkins JP; Leahy M; Gregory JJ
    Eur J Surg Oncol; 2016 Apr; 42(4):574-80. PubMed ID: 26831007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.
    Robertson NL; Sala E; Benz M; Landa J; Scardino P; Scher HI; Hricak H; Vargas HA
    J Urol; 2017 Jul; 198(1):65-70. PubMed ID: 28216327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body MRI of neuroblastoma.
    Goo HW
    Eur J Radiol; 2010 Sep; 75(3):306-14. PubMed ID: 19781884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.
    Wang L; Hricak H; Kattan MW; Schwartz LH; Eberhardt SC; Chen HN; Scardino PT
    AJR Am J Roentgenol; 2006 Mar; 186(3):743-8. PubMed ID: 16498101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients.
    Portalez D; Mozer P; Cornud F; Renard-Penna R; Misrai V; Thoulouzan M; Malavaud B
    Eur Urol; 2012 Dec; 62(6):986-96. PubMed ID: 22819387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.